Sorted By Test Name - Mayo Medical Laboratories

FAMAN
91132
AMKPK
82112
possible even with metastasis, although the long-term disease-related mortality rate is high. ASPS is
characterized by a translocation that results in fusion of TFE3 on chromosome Xp11.2 with ASPSCR1
(also called ASPL or RCC17) on chromosome 17q25.3.(1,2) Both balanced and unbalanced forms (loss of
the derivative X chromosome) of the translocation have been observed.(2,3) Another tumor, a rare subset
of papillary renal cell carcinoma (RCC) with a distinctive pathologic morphology, has rearrangements of
TFE3 with ASPSCR1 or other fusion partner genes.(1,4,5) This tumor predominantly affects children and
young adults, presents at an advanced stage but with an indolent clinical course, and is a distinct entity in
the World Health Organization classification.(6) Typically a balanced form of the translocation is present
in the RCC variant. An assay to detect rearrangement of TFE3 is useful to resolve diagnostic uncertainty
in these tumor types, as immunohistochemistry for TFE3 is not reliable.
Useful For: Aids in the diagnosis of alveolar soft-part sarcoma or renal cell carcinoma variant when
used in conjunction with an anatomic pathology consultation
Interpretation: A neoplastic clone is detected when the percent of nuclei with the abnormality exceeds
the established normal cutoff for the TFE3 probe set. A positive result of TFE3 rearrangement is
consistent with a diagnosis of alveolar soft-part sarcoma (ASPS) or renal cell carcinoma (RCC) variant. A
negative result suggests that TFE3 is not rearranged, but does not exclude the diagnosis of ASPS or RCC
variant.
Reference Values:
An interpretive report will be provided.
Clinical References: 1. Zhong M, De Angelo P, Osborne L, et al: Dual-color break-apart FISH
assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma
and alveolar soft part sarcoma. Am J Surg Pathol 2010;34(6):757-766 2. Ladanyi M, Lui MY, Antonescu
CR, et al: The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription
factor gene to ASPL, a novel gene at 17q25. Oncogene 2001;20:48-57 3. Williams A, Bartle G, Vaiyapuri
SP, et al: Detection of ASPL/TFE3 fusion transcripts and the TFE3 antigen in formalin-fixed,
paraffin-embedded tissue in a series of 18 cases of alveolar soft part sarcoma: Useful diagnostic tools in
cases with unusual histologic features. Virchows Arch 2011;458:291-300 4. Ross H, Argani P: Xp11
translocation renal cell carcinoma. Pathology 2010;42(4):369-373 5. Armah HB, Parwani AV: Xp11.2
translocation renal cell carcinoma. Arch Pathol Lab Med 2010;134:124-129 6. WHO Classification of
Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs In IARC
WHO Classification of Tumours. Edited by JN Eble, et al. Lyon: IARC Press, 2004, pp 37-38
Amantadine (Symmetrel)
Reference Values:
Therapeutic range has not been established.
expected steady state amantadine concentrations in
patients receiving recommended daily dosages:
200-1000 ng/mL
Toxicity reported at greater than 2000 ng/mL
Test Performed by: Medtox Laboratories, Inc.
402 W. County Road D
St. Paul, MN. 55112
Amikacin, Peak, Serum
Clinical Information: Amikacin is an aminoglycoside used to treat severe blood infections by
susceptible strains of gram-negative bacteria. Aminoglycosides induce bacterial death by irreversibly
binding bacterial ribosomes to inhibit protein synthesis. Amikacin is minimally absorbed from the
gastrointestinal tract, and thus can been used orally to reduce intestinal flora. Peak serum concentrations
are seen 30 minutes after intravenous infusion, or 60 minutes after intramuscular administration. Serum
half-lives in patients with normal renal function are generally 2 to 3 hours. Excretion of aminoglycosides
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 108